• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.

出版信息

Obes Facts. 2016;9(2):65-90. doi: 10.1159/000443344. Epub 2016 Apr 8.

DOI:10.1159/000443344
PMID:27055256
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5644799/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/377e/5644799/8d546bfb0caf/ofa-0009-0065-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/377e/5644799/8d546bfb0caf/ofa-0009-0065-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/377e/5644799/8d546bfb0caf/ofa-0009-0065-g01.jpg

相似文献

1
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.欧洲肝脏研究学会（EASL）-欧洲糖尿病研究学会（EASD）-欧洲肥胖症研究学会（EASO）非酒精性脂肪性肝病管理临床实践指南
Obes Facts. 2016;9(2):65-90. doi: 10.1159/000443344. Epub 2016 Apr 8.
2
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.欧洲肝脏研究学会-欧洲糖尿病研究学会-欧洲肥胖症研究学会非酒精性脂肪性肝病管理临床实践指南
J Hepatol. 2016 Jun;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004. Epub 2016 Apr 7.
3
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.欧洲肝脏研究学会-欧洲糖尿病研究学会-欧洲肥胖症研究学会非酒精性脂肪性肝病管理临床实践指南
Diabetologia. 2016 Jun;59(6):1121-40. doi: 10.1007/s00125-016-3902-y.
4
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: disease mongering or call to action?欧洲肝脏研究学会-欧洲糖尿病研究学会-欧洲肥胖症研究学会非酒精性脂肪性肝病管理临床实践指南：是疾病兜售还是行动呼吁？
Diabetologia. 2016 Jun;59(6):1145-7. doi: 10.1007/s00125-016-3930-7. Epub 2016 Apr 7.
5
Comment to: "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease".对《欧洲肝脏研究学会-欧洲糖尿病研究学会-欧洲肥胖研究学会非酒精性脂肪性肝病管理临床实践指南》的评论
J Hepatol. 2017 Feb;66(2):465-466. doi: 10.1016/j.jhep.2016.10.036. Epub 2016 Nov 14.
6
Response to: Comment to "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease".对《关于〈非酒精性脂肪性肝病管理的欧洲肝脏研究学会-欧洲糖尿病研究学会-欧洲肥胖症研究学会临床实践指南〉的评论》的回应
J Hepatol. 2017 Feb;66(2):466-467. doi: 10.1016/j.jhep.2016.11.002. Epub 2016 Nov 14.
7
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: guidelines, clinical reality and health economic aspects.欧洲肝脏研究学会-欧洲糖尿病研究学会-欧洲肥胖症研究学会非酒精性脂肪性肝病管理临床实践指南：指南、临床实际情况及卫生经济学方面
Diabetologia. 2016 Jun;59(6):1148-9. doi: 10.1007/s00125-016-3941-4. Epub 2016 Apr 7.
8
Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German Obesity Society.德国肥胖学会成员对德国以及欧洲肝脏研究学会（EASL）、欧洲糖尿病研究学会（EASD）和欧洲肥胖研究学会（EASO）非酒精性脂肪性肝病指南的了解与实践情况。
Dig Liver Dis. 2018 Jul;50(7):731-733. doi: 10.1016/j.dld.2018.03.029. Epub 2018 Mar 30.
9
Publisher Correction: EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.出版商更正：欧洲肝脏研究学会（EASL）-欧洲糖尿病研究学会（EASD）-欧洲肥胖症研究学会（EASO）代谢功能障碍相关脂肪性肝病（MASLD）管理临床实践指南：执行摘要。
Diabetologia. 2024 Nov;67(11):2608. doi: 10.1007/s00125-024-06258-6.
10
Should the new EASL-EASD-EASO Clinical Practice Guidelines on MASLD recommend pioglitazone as a MASH-targeted pharmacotherapy?新版欧洲肝脏研究学会（EASL）-欧洲糖尿病研究学会（EASD）-欧洲肥胖症研究学会（EASO）非酒精性脂肪性肝病（MAFLD）临床实践指南是否应推荐吡格列酮作为针对MAFLD的药物治疗？
J Hepatol. 2025 Jan;82(1):e21-e22. doi: 10.1016/j.jhep.2024.06.034. Epub 2024 Jul 4.

引用本文的文献

1
Global Trends in Non-Invasive Techniques for the Diagnosis and Monitoring of Nonalcoholic Fatty Liver Disease: A Bibliometric and Visualization Analysis.非酒精性脂肪性肝病诊断与监测的非侵入性技术全球趋势：文献计量与可视化分析
J Multidiscip Healthc. 2025 Jul 26;18:4243-4266. doi: 10.2147/JMDH.S525751. eCollection 2025.
2
Efficacy of orlistat for the treatment of metabolic dysfunction-associated steatotic liver disease patients: A systematic review and meta-analysis.奥利司他治疗代谢功能障碍相关脂肪性肝病患者的疗效：一项系统评价和荟萃分析。
Hepatol Forum. 2025 May 22;6(3):129-136. doi: 10.14744/hf.2024.2024.0047. eCollection 2025.
3

本文引用的文献

1
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.利拉鲁肽治疗非酒精性脂肪性肝炎（LEAN）患者的安全性和有效性：一项多中心、双盲、随机、安慰剂对照的 2 期研究。
Lancet. 2016 Feb 13;387(10019):679-690. doi: 10.1016/S0140-6736(15)00803-X. Epub 2015 Nov 20.
2
Statin use and non-alcoholic steatohepatitis in at risk individuals.他汀类药物的使用与高危个体的非酒精性脂肪性肝炎。
J Hepatol. 2015 Sep;63(3):705-12. doi: 10.1016/j.jhep.2015.05.006. Epub 2015 May 14.
3
Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis.
Discovery of the First Highly Selective 1,4-dihydropyrido[3,4-]pyrazin-3(2H)-one MKK4 Inhibitor.
首个高选择性1,4-二氢吡啶并[3,4-]吡嗪-3(2H)-酮MKK4抑制剂的发现。
J Med Chem. 2025 Jul 24;68(14):14782-14805. doi: 10.1021/acs.jmedchem.5c00919. Epub 2025 Jul 11.
4
MAFLD was more easily diagnosed than NAFLD in liver transplant recipients with abnormal liver function.在肝功能异常的肝移植受者中，MAFLD比NAFLD更容易诊断。
ILIVER. 2022 Sep 20;1(3):194-198. doi: 10.1016/j.iliver.2022.09.001. eCollection 2022 Sep.
5
A nomogram for predicting metabolic-associated fatty liver disease in non-obese newly diagnosed type 2 diabetes patients.用于预测非肥胖新诊断2型糖尿病患者代谢相关脂肪性肝病的列线图。
Front Endocrinol (Lausanne). 2025 May 29;16:1521168. doi: 10.3389/fendo.2025.1521168. eCollection 2025.
6
Accelerated Biological Aging, Genetic Susceptibility, and Non-Alcoholic Fatty Liver Disease: Two Prospective Cohort Studies.加速生物衰老、遗传易感性与非酒精性脂肪性肝病：两项前瞻性队列研究
Nutrients. 2025 May 8;17(10):1618. doi: 10.3390/nu17101618.
7
Challenges and needs in the management of non-alcoholic fatty liver disease from the perspective of gastroenterology and hepatology specialists: a qualitative study.从胃肠病学和肝病学专家角度看非酒精性脂肪性肝病管理中的挑战与需求：一项定性研究
BMC Gastroenterol. 2025 May 22;25(1):396. doi: 10.1186/s12876-025-03921-z.
8
Exosome-derived miR-548ag drives hepatic lipid accumulation via upregulating FASN through inhibition of DNMT3B.外泌体来源的miR-548ag通过抑制DNMT3B上调FASN来驱动肝脏脂质积累。
J Lipid Res. 2025 May 6;66(6):100818. doi: 10.1016/j.jlr.2025.100818.
9
Mediation Analyses Link Cardiometabolic Factors and Liver Fat With White Matter Hyperintensities and Cognitive Performance: A UK Biobank Study.中介分析将心脏代谢因素和肝脏脂肪与脑白质高信号及认知表现联系起来：一项英国生物银行研究
Biol Psychiatry Glob Open Sci. 2025 Mar 20;5(4):100488. doi: 10.1016/j.bpsgos.2025.100488. eCollection 2025 Jul.
10
The insight to history and trends of transient elastography for assessing liver fibrosis-a bibliometric analysis.用于评估肝纤维化的瞬时弹性成像技术的历史与趋势洞察——一项文献计量分析
Quant Imaging Med Surg. 2025 Apr 1;15(4):2971-2986. doi: 10.21037/qims-24-2117. Epub 2025 Mar 13.
非酒精性脂肪肝患者的肝线粒体功能适应在脂肪性肝炎中丧失。
Cell Metab. 2015 May 5;21(5):739-46. doi: 10.1016/j.cmet.2015.04.004.
4
Current efforts and trends in the treatment of NASH.目前治疗 NASH 的方法和趋势。
J Hepatol. 2015 Apr;62(1 Suppl):S65-75. doi: 10.1016/j.jhep.2015.02.041.
5
Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients.肥胖症手术可减轻病态肥胖患者非酒精性脂肪性肝炎的特征。
Gastroenterology. 2015 Aug;149(2):379-88; quiz e15-6. doi: 10.1053/j.gastro.2015.04.014. Epub 2015 Apr 25.
6
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis.欧洲肝脏研究学会-阿莱赫临床实践指南：用于评估肝脏疾病严重程度和预后的非侵入性检查
J Hepatol. 2015 Jul;63(1):237-64. doi: 10.1016/j.jhep.2015.04.006. Epub 2015 Apr 21.
7
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.通过生活方式改变减轻体重可显著改善非酒精性脂肪性肝炎的特征。
Gastroenterology. 2015 Aug;149(2):367-78.e5; quiz e14-5. doi: 10.1053/j.gastro.2015.04.005. Epub 2015 Apr 10.
8
Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop.非酒精性脂肪性肝炎药物及生物标志物开发中的挑战与机遇：美国肝病研究协会-美国食品药品监督管理局联合研讨会的结果与建议
Hepatology. 2015 Apr;61(4):1392-405. doi: 10.1002/hep.27678. Epub 2015 Mar 19.
9
Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial).依泽替米贝治疗非酒精性脂肪性肝炎：一项随机试验（莫扎特试验）中采用新型磁共振成像和磁共振弹性成像的评估
Hepatology. 2015 Apr;61(4):1239-50. doi: 10.1002/hep.27647. Epub 2015 Feb 27.
10
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.使用配对活检评估非酒精性脂肪性肝病从脂肪变性进展为纤维性脂肪性肝炎的证据：对预后和临床管理的影响。
J Hepatol. 2015 May;62(5):1148-55. doi: 10.1016/j.jhep.2014.11.034. Epub 2014 Dec 1.